Prostate-specific antigen (PSA) should drive doing prostate biopsies

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 1, 2012, Pages 1-2

  Loeb, Stacy ^a   Catalona, William J ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER MORTALITY; COLORECTAL CANCER; EDITORIAL; FOLLOW UP; HUMAN; LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCREENING; UNITED STATES;

BIOPSY; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84855649883     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.10.007     Document Type: Editorial

References (13)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Cancer Facts and Figures 2010 American Cancer Society, Accessed September 20, 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf.
3. Walter L.C., Bertenthal D., Lindquist K., et al. PSA screening among elderly men with limited life expectancies. JAMA 2006, 296:2336-2342.
4. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725-732.
5. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
6. Pinsky P.F., Andriole G.L., Kramer B.S., et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal, and ovarian cancer screening trial. J Urol 2005, 173:746-750. Discussion 750.
7. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
8. Loeb S, Vonesh EF, Metter EJ, et al. What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing? J Clin Oncol, in press.
9. van Leeuwen P.J., Connolly D., Gavin A., et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 2010, 46:377-383.
10. Smith J.A. What would you do, doctor?. J Urol 2009, 182:421-422.
11. Loeb S., Roehl K.A., Helfand B.T., et al. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?. J Urol 2010, 183:112-116.
12. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006, 98:1521-1527.
13. Jansen F.H., van Schaik R.H., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57:921-927.